Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis
Objectives To evaluate the cost-effectiveness of the 9-valent human papillomavirus (HPV) vaccine for the prevention of cervical cancer in China.Design Health economic modelling using the Papillomavirus Rapid Interface for Modelling and Economics (PRIME) model populated with China-specific data.Setti...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2019-11-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/9/11/e031186.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846126396024291328 |
|---|---|
| author | Jing Wu Y Jiang Weiyi Ni |
| author_facet | Jing Wu Y Jiang Weiyi Ni |
| author_sort | Jing Wu |
| collection | DOAJ |
| description | Objectives To evaluate the cost-effectiveness of the 9-valent human papillomavirus (HPV) vaccine for the prevention of cervical cancer in China.Design Health economic modelling using the Papillomavirus Rapid Interface for Modelling and Economics (PRIME) model populated with China-specific data.Setting Individual cervical cancer prevention in China using the 9-valent HPV vaccine from the perspective of private sector purchasers in relation to receiving other HPV vaccines and not receiving vaccination for 16-year-old girls in China who had not been previously infected with HPV.Participants Not applicable.Interventions Vaccination using the 9-valent, the quadrivalent and the bivalent vaccines.Primary outcome measure Incremental costs per disability-adjusted life year (DALY) prevented.Results In the base case, the incremental costs per DALY prevented were, respectively, US$35 000 and US$50 455 compared with the quadrivalent and the bivalent vaccines, both of which were above the cost-effective threshold of US$25 920/DALY prevented. To be cost-effective in these comparisons, the 9-valent vaccine should be priced at $550 and $450 for the full doses, respectively. To be highly cost-effective, the price thresholds were $435 and $335. The incremental costs per DALY prevented in relation to no vaccination was US$23 012, making the 9-valent vaccine marginally cost-effective. The results were robust in most one-way sensitivity analyses including changing vaccination age to 13 and 26 years.Conclusions At the current price, the 9-valent HPV vaccine is not cost-effective compared with the quadrivalent and the bivalent vaccines for young girls in China who had not been previously infected with HPV. Policymakers and clinicians should keep potential vaccine recipients informed about the economic profile of the 9-valent vaccine and carefully consider expanding its use in China at the current price. |
| format | Article |
| id | doaj-art-fe24b8503ec54717bbf1c01c7f0578c1 |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2019-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-fe24b8503ec54717bbf1c01c7f0578c12024-12-12T23:15:08ZengBMJ Publishing GroupBMJ Open2044-60552019-11-0191110.1136/bmjopen-2019-031186Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysisJing Wu0Y Jiang1Weiyi Ni23 School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, ChinaRheumatology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, ChinaDepartment of Pharmaceutical and Health Economics, University of Southern California, Los Angeles, California, USAObjectives To evaluate the cost-effectiveness of the 9-valent human papillomavirus (HPV) vaccine for the prevention of cervical cancer in China.Design Health economic modelling using the Papillomavirus Rapid Interface for Modelling and Economics (PRIME) model populated with China-specific data.Setting Individual cervical cancer prevention in China using the 9-valent HPV vaccine from the perspective of private sector purchasers in relation to receiving other HPV vaccines and not receiving vaccination for 16-year-old girls in China who had not been previously infected with HPV.Participants Not applicable.Interventions Vaccination using the 9-valent, the quadrivalent and the bivalent vaccines.Primary outcome measure Incremental costs per disability-adjusted life year (DALY) prevented.Results In the base case, the incremental costs per DALY prevented were, respectively, US$35 000 and US$50 455 compared with the quadrivalent and the bivalent vaccines, both of which were above the cost-effective threshold of US$25 920/DALY prevented. To be cost-effective in these comparisons, the 9-valent vaccine should be priced at $550 and $450 for the full doses, respectively. To be highly cost-effective, the price thresholds were $435 and $335. The incremental costs per DALY prevented in relation to no vaccination was US$23 012, making the 9-valent vaccine marginally cost-effective. The results were robust in most one-way sensitivity analyses including changing vaccination age to 13 and 26 years.Conclusions At the current price, the 9-valent HPV vaccine is not cost-effective compared with the quadrivalent and the bivalent vaccines for young girls in China who had not been previously infected with HPV. Policymakers and clinicians should keep potential vaccine recipients informed about the economic profile of the 9-valent vaccine and carefully consider expanding its use in China at the current price.https://bmjopen.bmj.com/content/9/11/e031186.full |
| spellingShingle | Jing Wu Y Jiang Weiyi Ni Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis BMJ Open |
| title | Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis |
| title_full | Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis |
| title_fullStr | Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis |
| title_full_unstemmed | Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis |
| title_short | Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis |
| title_sort | cost effectiveness and value based prices of the 9 valent human papillomavirus vaccine for the prevention of cervical cancer in china an economic modelling analysis |
| url | https://bmjopen.bmj.com/content/9/11/e031186.full |
| work_keys_str_mv | AT jingwu costeffectivenessandvaluebasedpricesofthe9valenthumanpapillomavirusvaccineforthepreventionofcervicalcancerinchinaaneconomicmodellinganalysis AT yjiang costeffectivenessandvaluebasedpricesofthe9valenthumanpapillomavirusvaccineforthepreventionofcervicalcancerinchinaaneconomicmodellinganalysis AT weiyini costeffectivenessandvaluebasedpricesofthe9valenthumanpapillomavirusvaccineforthepreventionofcervicalcancerinchinaaneconomicmodellinganalysis |